Evidence map›Paper›PMID 41407308›Full record

ReviewClinical pharmacology and therapeutics2026

Guided Sample Pooling in Human Mass Balance Studies: A Recommended Strategic Decision Framework.

Filip Cuyckens, Wenying Li, Adam M Auclair, Kenneth C Cassidy, Cathy Cantalloube, Gary Collins, Alexander D James, Chris Gibson, Ulrike Glaenzel, Felix Huth and 12 more

Abstract readReview
In one paragraph

Review in Clinical pharmacology and therapeutics, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

22 authors.

Filip CuyckensJohnson & Johnson, Beerse, Belgium.ORCID 0000-0003-4956-1418
Wenying LiBristol-Myers Squibb, Princeton, New Jersey, USA.ORCID 0009-0005-6340-8286
Adam M AuclairBoehringer Ingelheim Pharmaceuticals, Inc., Ridgefield, Connecticut, USA.ORCID 0000-0001-6507-237X
Kenneth C CassidyEli Lilly and Company, Indianapolis, Indiana, USA.
Cathy CantalloubeSanofi, Vitry sur-Seine, France.ORCID 0000-0002-3083-5362
Gary CollinsGlaxoSmithKline, Stevenage, UK.ORCID 0000-0002-3717-2231
Alexander D JamesNovartis Pharma AG, Basel, Switzerland.ORCID 0000-0002-8420-2456
Chris GibsonIncyte, Wilmington, Delaware, USA.ORCID 0000-0002-1719-8629
Ulrike GlaenzelNovartis Pharma AG, Basel, Switzerland.
Felix HuthNovartis Pharma AG, Basel, Switzerland.ORCID 0000-0002-7121-4394
Ping KangVertex, San Diego, California, USA.
Patricia MolinerSanofi, Montpellier, France.ORCID 0009-0004-6066-9977
Mette L PedersenAstraZeneca, Gothenburg, Sweden.ORCID 0009-0005-2290-3934
Isabel PielBayer AG, Wuppertal, Germany.ORCID 0000-0002-6745-3069
Pietro BrunettiF. Hofmann-La Roche, Basel, Switzerland.ORCID 0000-0001-5271-7773
Hanno SchiefersteinThe Healthcare Business of Merck KGaA, Darmstadt, Germany.ORCID 0009-0004-4497-0516
David WagnerAbbVie Inc., North Chicago, Illinois, USA.ORCID 0009-0007-3649-5673
Gregory S WalkerPfizer, Groton, Connecticut, USA.ORCID 0000-0003-0129-1682
Shuai WangGenentech, Inc., South San Francisco, California, USA.ORCID 0000-0002-3282-1343
Qin YueGilead Sciences, Foster City, California, USA.ORCID 0009-0007-6326-458X
Jason BoerIncyte, Wilmington, Delaware, USA.ORCID 0009-0008-5628-0028
Cyrus KhojastehGenentech, Inc., South San Francisco, California, USA.ORCID 0000-0002-8385-9288

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Radiolabeled human mass balance studies are crucial for identifying circulating metabolites and understanding drug absorption, excretion, and clearance pathways. Metabolite profiling involves quantifying all drug-related entities, including parent drug and metabolites in plasma and excreta, using extended liquid chromatography methods coupled with detection through scintillation counting, accelerator mass spectrometry, or non-radiolabeled approaches. Given the labor-intensive nature of sample extraction and analysis, we propose a new paradigm that maximizes gathering information through sample pooling strategies. Our proposal introduces sample pooling strategies by integrating both individual and pooled sample schemes, simplifying decisions, and consolidating existing knowledge into a cohesive document. This aligns with the low statistical power typically associated with mass balance studies that dose six to eight subjects. In metabolite profiling, it is common practice to pool samples either from the limited number of subjects participating in a human mass balance study or from different time points of sample collection. This approach improves efficiency while preserving data integrity. Pooling reduces resource constraints and enables the concentration of samples with relatively low radioactivity levels, resulting in higher quality metabolite profiles. Nevertheless, there are situations when analyzing samples from individual subjects or time points may be preferred. This proposal presents guidance and decision trees designed to facilitate informed decisions about sample pooling to maximize data quality of metabolite profiling in human mass balance studies while efficiently managing resources. These recommendations stem from discussions within the mass balance working group of the IQ Consortium.

Indexed as

Chromatography, LiquidHumansMass SpectrometryPharmaceutical PreparationsPharmaceutical Preparations

Identifiers

PMID41407308
PMCPMC12882751

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.